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Abbreviations and acronyms 
95%CI: 95% confidence interval; ACS: acute coronary syndrome; aHR: adjusted hazard ratio; BMI: body 
mass index; BPAR: biopsy-proven acute rejection; CAD: coronary artery disease; CKD-EPI: Chronic Kidney 
Disease Epidemiology Collaboration equation; CMV: cytomegalovirus; CVA: cerebrovascular accident; DC: 
dendritic cell; DCD: donation after circulatory death; DNA: deoxyribonucleic acid; DSA: donor-specific 
antibodies; eGFR: estimated glomerular filtration rate; ELISA: enzyme-linked immunosorbent assay; HDL-
cholesterol: high-density lipoprotein cholesterol; HLA: human leucocyte antigen; IFN-ɣ: interferon gamma; 
IQR: interquartile range; KTR: kidney transplant recipient; LDL-cholesterol: low-density lipoprotein 
cholesterol; MACCE: major adverse cardiac and cerebrovascular event; MFI: mean fluorescence intensity; 
MHC: major histocompatibility complex; PAD: peripheral artery disease; (c)PRA: (calculated) panel reactive 
antibodies; mTOR: mammalian target of rapamycin; non-STEMI: non-ST-segment elevation myocardial 
infarction; OxLDL: oxidized LDL-cholesterol; PCR: polymerase chain reaction; PCR-SSO: sequence-
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specific oligohybridisation primed PCR; PCR-SSP: sequence-specific primer PCR; SLE: systemic lupus 
erythematosus; STEMI: ST-segment elevation myocardial infarction; TIA: transient ischemic attack; Tfh 
cells: follicular helper T cells; TNF: tumor necrosis factor.  
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ABSTRACT 
Background. The negative role of HLA class II DSA on graft outcome is well-recognized. However, the 
potentially negative cardiovascular effects of preformed HLA class II antibodies and donor HLA in kidney 
transplant recipients (KTR) remain unestablished.  
Methods. We conducted a single-centre, retrospective cohort study including 1115 KTR (2003-2016) with up 
to 4449 person-years of follow-up after transplantation and a median follow-up time of 5.1 years (IQR: 2.7-
7.6). We evaluated the unadjusted and multivariable-adjusted association between pretransplant HLA class I 
and II antibodies, as well as HLA-DR1 donor/recipient genotype and the primary (MACCE or all-cause 
mortality) and secondary (MACCE or cardiovascular mortality) outcome. 
Results. In a multivariate Cox proportional hazard model, HLA class II antibodies prior to transplantation 
were associated with increased adjusted hazard ratio (aHR) for MACCE or all-cause mortality (aHR 1.71 
[1.13-2.60]; p=0.012) even after adjustment for time-varying covariates graft loss (aHR 1.68 [1.08-2.62]; 
p=0.022) and biopsy-proven acute rejection (aHR 1.71 [1.13-2.60]; p=0.012). HLA class II antibodies were 
also associated with increased aHR for the secondary outcome, MACCE or cardiovascular mortality (aHR 
1.92 [1.12-3.30]; p=0.018). We investigated the effect of donor and recipient HLA-DR1 on these outcome 
parameters and demonstrated that KTR with HLA-DR1 positive donors had an increased aHR for MACCE 
with all-cause (aHR1.45 [1.09-1.94], p=0.012) and cardiovascular mortality (aHR1.49 [1.00-2.22], p=0.05).  
Conclusions. Prior sensitization against HLA class II antigens is associated with unfavourable long-term 
cardiovascular outcome in KTR independent of graft loss or rejection. Recipients of a HLA-DR1 donor also 
have an impaired cardiovascular outcome. 
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Introduction 
In the general population, the immune system is involved in the pathogenesis of hypertension, atherosclerosis, 
coronary artery disease (CAD) and hence cardiovascular disease (CVD).
1-3 
Emerging evidence suggests that 
the same might hold true in transplant recipients.
4-6 
 Atherosclerosis is the leading cause of CVD and 
inflammatory components participate at each stage of atherogenesis.
2,7-9 
Genes involved in inflammation are 
associated with progression of CAD in rheumatoid arthritis, inflammatory polyarthritis, systemic lupus 
erythematosus (SLE), type 1 diabetes and in heart transplant recipients.
9-12 
 The increased risk of 
cardiovascular events in auto-immune disease suggests that autoimmunity and CVD are intertwined.  
The major histocompatibility complex (MHC) is involved in both the recognition of foreign antigens and the 
development of autoimmune diseases.
13,14
 HLA class II is up-regulated in autoimmune disease and 
atherosclerosis where it is expressed on dendritic, smooth-muscle and inflammatory cells within the 
atherosclerotic plaque.
15,16 
It seems plausible that pro-inflammatory HLA antibodies could cause endothelial 
dysfunction and affect cardiovascular outcome.
5,6,17
 Also certain HLA class II antigens, in particular HLA-
DR1, are associated with increased cardiovascular risk in different populations probably through endothelial 
dysfunction and pro-inflammatory characteristics.
2,10-12,15,18-21
 In lung transplant recipients, specific HLA-DR 
donor serotypes significantly affect lung graft outcome.
22
 
Considering that the presence of certain HLA class II molecules (HLA-DR1) and HLA class II antibodies are 
associated with increased cardiovascular risk, we speculated that this might also hold true for kidney 
transplant recipients (KTR) independent of graft function. Our primary objective was to assess and compare 
the long-term outcome in KTR with versus without preformed especially HLA class II or class I antibodies. 
Our second objective was to assess the same outcome parameters in KTR according to recipient and donor 
HLA-DR1 genotype. 
Materials and Methods 
Summary 
We conducted a single-centre, retrospective cohort study including 1115 adult KTR who underwent 
transplantation between January 1, 2003 and December 31, 2016 with follow-up until loss to follow-up or 
November 30, 2017. Using Cox proportional hazard regression modelling we evaluated the unadjusted and 
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multivariable-adjusted association between quarterly determined pretransplant HLA class I and II antibodies, 
as well as HLA-DR1 donor/recipient genotype and the primary (MACCE or all-cause mortality) and 
secondary (MACCE or cardiovascular) outcome. 
Setting 
A preexisting database containing data on all adult (aged ≥18 years) KTR who underwent transplantation at 
Ghent University Hospital (Ghent, Belgium) since 2003 was used to obtain relevant transplant baseline 
characteristics. We censored patients at time of death, loss to follow-up or November 30, 2017. 
Study participants 
We conducted a single-centre cohort study including 1115 adult KTR who underwent transplantation between 
January 1, 2003 and December 31, 2016. Details about immunosuppressive and prophylactic drugs are 
described in the “Supporting Information” section. In patients with previous kidney transplantation, we 
analysed the outcome of the last transplantation. The study was approved by the local ethics committee 
(B670201731678) and is in agreement with the principles of the Declaration of Helsinki. 
Exposure and outcome definition 
Primary exposure 
The primary exposure was the presence of circulating HLA class I or II antibodies determined at quarterly 
intervals in waitlisted patients. Anti-HLA antibody screening was performed with an ELISA method 
(Lifecodes) from 2003 to 2008 and later with a Recombinant Single Antigen Bead assay on a Luminex 
platform (Lifecodes/Immucor). From 2012 on, anti-HLA antibody screening was considered positive if the 
mean fluorescence intensity (MFI) was ≥500. We define antigens as unacceptable and preclude 
transplantation when donor-specific antibodies (DSA) have MFI >2000. 
Secondary exposure 
Routine HLA class II typing of recipient and donor for HLA-DR1 was performed by DNA typing methods 
using sequence-specific oligo-hybridisation primed polymerase chain reaction (PCR-SSO) for patient and 
retrospective organ donor typing; and sequence-specific primer PCR (PCR-SSP) for donor typing. 
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
6 
 
Primary outcome 
The primary outcome of interest was time to composite end-point of major adverse cardiac and 
cerebrovascular events (MACCE), defined by acute coronary syndrome (ACS) including ST-segment 
elevation (STEMI), non-ST-segment elevation myocardial infarction (non-STEMI), unstable angina or 
coronary revascularization, transient ischemic attack (TIA) and cerebrovascular accident (CVA) or all-cause 
mortality. 
Secondary outcome 
The secondary outcome was time to MACCE or cardiovascular death. Cardiovascular death was defined as 
death attributable to ACS, heart failure or sudden cardiac death. 
Covariates 
We extracted patient characteristics and outcome data from a compiled preexisting database which registers 
an extensive list of covariates which are described in the “Supporting Information” section.  
We recorded the time to biopsy-proven acute rejection (BPAR), defined as acute T-cell mediated or antibody-
mediated rejection as interpreted by the pathologist according to Banff classification. We also recorded time 
to graft loss, defined as the permanent (>30 days) need for renal replacement therapy. We also registered the 
estimated glomerular filtration rate (eGFR) using the abbreviated four-variable Chronic Kidney Disease 
Epidemiology Collaboration equation (CKD-EPI) at three months, one, three and five years.
23
 
Statistical analysis 
We summarized descriptive statistics as mean ± standard deviation (SD) for normally distributed continuous 
variables or median with interquartile range (IQR) for skewed distributions. We performed pairwise deletion 
to handle missing values; however, apart from eGFR and cholesterol measurements, less than 1% of covariate 
data were missing.  
We created a graphical representation of causal effects between variables by the causal directed acyclic graph 
(DAG) approach in order to visualize the relationships between exposure and outcome of interest as well as 
associated variables (Figure S1, SDC, http://links.lww.com/TP/B783). We plotted Kaplan-Meier survival 
curves for primary and secondary outcomes in patients with versus without HLA class I or II antibodies and 
compared them by log-rank test. We used Cox proportional hazard regression to evaluate the unadjusted and 
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multivariable-adjusted association between HLA class I and II antibodies and the primary and secondary 
outcome. We assessed the assumption of proportionality for each covariate by constructing log cumulative 
hazard plots and by visually examining the Kaplan-Meier plots.  
We designed a series of models including an unadjusted (Model 1) and multivariable-adjusted (Models 2 to 4) 
Cox proportional hazard regression model with backward elimination to relate the primary exposure (the 
presence of HLA class II antibodies) with the primary and secondary outcome of interest. Model 2 included 
covariates associated with graft outcome based on existing literature and covariates with P value of <0.1 in the 
univariate analysis (Supplemental Data, SDC, http://links.lww.com/TP/B783): recipient age, recipient sex, 
panel reactive antibodies (PRA), retransplantation, smoking status, polyclonal induction, baseline CVD and 
diabetes mellitus. In Model 3 and 4 we used the covariates of Model 2, but respectively adjusted for BPAR 
and graft loss as time-dependent covariate. We also conducted additional analyses by stratifying for year of 
transplantation (2003-2007 versus 2008-2016), since the sensitive Luminex-based identification of HLA 
antibodies was only used after 2007.  
We conducted additional secondary analyses to ascertain the robustness of our findings and analysed whether 
the presence of HLA class I or II antibodies would have different effects on MACCE with all-cause or 
cardiovascular mortality in specific subgroups: recipient age ≤ or >60 years, BPAR (yes/no), graft loss 
(yes/no) and retransplantation (yes/no). For each of these covariates, we analysed a potential statistical 
interaction with HLA antibody positivity.  
In an attempt to eliminate the effect of DSA, we performed separate analyses by excluding patients with DSA 
at time of transplantation in patients with preformed HLA class II antibodies. To explore the association 
between anti-HLA sensitization (calculated PRA, cPRA) and the primary outcome, we assessed the 
correlation by constructing scatter plots and calculating the Pearson (r) correlation coefficient. 
We also evaluated the unadjusted association between donor and recipient HLA-DR1 status and the same 
outcome parameters in the overall study population (Model 5). Although the allocation of HLA-DR1 donor 
kidney is at random, apart from allocation to HLA-DR1 positive recipients, we performed an additional 
multivariate-adjusted Cox proportional hazard regression model (Model 6) including covariates associated 
with graft outcome and covariates with P value <0.1 in the univariate analysis (Supplemental Data, SDC, 
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http://links.lww.com/TP/B783): recipient HLA-DR1 status, recipient age, recipient sex, smoking status, 
polyclonal induction, baseline CVD and diabetes mellitus. In Model 7 and 8 we used the covariates of Model 
6, but respectively adjusted for BPAR and graft loss as time-dependent covariate.  
Unadjusted and adjusted hazard ratios (aHR) were assessed with 95% confidence interval (95%CI). A two-
sided P value <0.05 was considered to indicate statistical significance for all analyses. Statistical analyses 
were performed with SPSS
®
 (IBM SPSS Statistics for Windows, version 25.0; Armonk, NY: IBM Corp). The 
study was reported in accordance with the Strengthening the Reporting of Observational Studies in 
Epidemiology statement.
24
 
Results 
Baseline characteristics 
In 828 of 1115 patients the presence of circulating HLA class I or II antibodies was measured prior to or at the 
time of transplantation (Figure S2, SDC, http://links.lww.com/TP/B783). Baseline characteristics of the study 
cohort and patients with HLA class II antibodies are described in Table 1. For more detailed information of 
the study cohort according to HLA class I and/or class II status we refer to Table S1 (SDC, 
http://links.lww.com/TP/B783). The median age of the study participants was 54 years, 62% were male and 
19% had diabetes mellitus at the time of transplantation. The total number of person-years of follow-up after 
transplantation was 4494 years and the median follow-up time was 5.1 years (IQR: 2.7-7.6).  
Meanwhile, 78 patients (9.4%) developed adverse cardiac and cerebrovascular events. Eighty-four patients 
(10.1%) died during follow-up: infections (N=22; 26.2%), cancer (N=17; 20.2%), cardiac (N=6, 7.1%), other 
(N=9; 10.7%) and unknown (N=30; 35.7%). A total of 138 patients (16.7%) had a MACCE or died and 79 
patients (9.5%) a MACCE or cardiovascular death. 
Overall, 74 (8.9%) participants had pretransplant HLA class I antibodies, 116 (14%) HLA class II antibodies 
and 41 (5%) had combined class I and II antibodies. The clinical characteristics of patients with and without 
preformed HLA class II antibodies are depicted in Table 1. Patients with versus without HLA class II 
antibodies were more often female, had more previous transplantations, PRA > 0% and received more 
polyclonal induction. 
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In the patients with HLA class II antibodies (N=116), 68 (58.6%) patients had no DSA, 14 (12.1%) had DSA 
and in 34 (29.3%) we have no data of DSA at time of transplantation. We lack data on DSA at time of 
transplantation in patients transplanted before 2008.  
BPAR occurred in 121 patients (14.8%) and graft loss in 60 patients (7.4%). The incidence of both did not 
differ between patients with or without HLA class I or II antibodies (respectively P = 0.243 and P = 0.570 for 
BPAR; P = 0.881 and P = 0.609 for graft loss). During follow-up, eGFR did not differ between participants 
with versus without HLA antibodies. 
Primary outcome analyses 
Participants with HLA class II antibodies had an estimated 65% higher hazard for MACCE or all-cause 
mortality than patients without HLA class II antibodies (95%CI of 1.09-2.49) (Figure 1a; Table 2: Model 1). 
The presence of HLA class II antibodies remained associated with an increased hazard for MACCE or all-
cause mortality in the multivariate model (aHR 1.71 with 95%CI of 1.13 to 2.60) (Table 2: Model 2). This 
risk remained increased when BPAR or graft loss were included as time-dependent covariates (Table 2: Model 
3 and 4).  
The presence of HLA class I antibodies was not statistically associated with a higher hazard for MACCE or 
all-cause mortality (Table 2: Model 1 to 4). 
Secondary outcome analyses 
In patients with versus without HLA class II antibodies, the secondary outcome analysis also revealed a 
higher event rate for MACCE or cardiovascular mortality (Figure 1b) with an unadjusted HR of 1.78 [95%CI, 
1.04 to 3.04] and a multivariate-adjusted HR of 1.92 [95%CI, 1.12 to 3.30] (Table 2: Model 1 and 2). 
Pretransplant HLA class II antibodies remained associated with MACCE or cardiovascular mortality when 
BPAR or graft loss were used as time-dependent covariates (Table 2: Model 3 and 4).  
HLA class I antibodies were not significantly associated with MACCE nor cardiovascular mortality (Table 2: 
Model 1 to 4).  
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Additional analyses 
In patients with versus without HLA class I or II antibodies, the unadjusted hazard ratio for all-cause mortality 
was not increased. However, the multivariable-adjusted hazard ratio for all-cause mortality in patients with 
HLA class II antibodies was increased with an aHR of 1.84 [95%CI, 1.05 to 3.22] (P = 0.033).  
The increased risk for MACCE or all-cause mortality in patients with versus without preformed HLA class II 
antibodies was confirmed in subgroup analyses excluding patients with BPAR or graft loss (aHR 1.88 
[95%CI, 1.22 to 2.92] and 1.98 [95%CI, 1.25 to 3.12] respectively). When excluding both groups the aHR 
increased even further to 2.20 [95%CI, 1.37 to 3.52] (Figure 2a). 
The increased risk for MACCE or cardiovascular mortality in patients with HLA class II antibodies was also 
confirmed in subgroup analyses excluding patients with BPAR or graft loss (aHR of 1.97 [95%CI, 1.10 to 
3.53] and 1.91 [95%CI, 1.08 to 3.40] respectively). When excluding both groups the aHR for MACCE or 
cardiovascular mortality increased even further to 2.09 [95%CI, 1.14-3.82] (Figure 2b). 
When patients with HLA class II antibodies and preformed DSA were excluded from the primary and 
secondary analyses, we found identical but more pronounced results (Table S2, SDC, 
http://links.lww.com/TP/B783).  
There was a clear correlation between the cPRA and the primary outcome of interest (Figure 3 and Figure S3, 
SDC, http://links.lww.com/TP/B783). 
By performing separate sensitivity analyses across different subgroups, we confirmed these findings in 
patients independent of age (recipient age ≤ or > 60 years) and in patients with a first kidney transplantation. 
There were no significant interactions between HLA class II antibodies and BPAR, graft loss, recipient age or 
retransplantation (Table 3, Figure 4). 
We also conducted additional analyses according to year of transplantation (2003-2007 versus 2008-2016) 
considering the Luminex-based identification of HLA antibodies since 2008. Our findings remained robust in 
KTR transplanted between 2008 and 2016 (Figure S4 and S5; Table S3, SDC, http://links.lww.com/TP/B783).  
We performed separate sub-analyses in patients uniquely induced by basiliximab: the HR of MACCE or all-
cause mortality was 1.65 (95%CI 1.09-2.49; p=0.019) in the univariate model and 1.71 (95%CI 1.13-2.60; 
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p=0.012) in the multivariate model. The HR of MACCE or cardiovascular mortality was 1.78 (95%CI 1.04-
3.04; p=0.036) in the univariate model and 1.92 (95%CI 1.12-3.30; p=0.018). 
Donor HLA class II antigens 
Overall (N=1115), 238 (21.3%) participants were HLA-DR1 positive, 227 (20.4%) had a HLA-DR1 positive 
donor and 145 (13%) were HLA-DR1 donor and recipient positive. 
The unadjusted HR for all-cause mortality for patients with versus without HLA-DR1 donor was not 
significantly increased (HR 1.41 [95%CI, 0.99 – 2.00], P = 0.056). However, KTR with versus without HLA-
DR1 positive donors had more cardiovascular events (Figure 5a) with an unadjusted and adjusted HR for 
MACCE or all-cause mortality of 1.45 [95%CI, 1.09-1.94] and 1.72 [95%CI, 1.31-2.26] respectively (Table 4: 
Model 5 and 6). The risk for MACCE or all-cause mortality when either BPAR or graft loss were used as a 
time-dependent covariate remained increased (Table 4: Model 7 and 8). However, the presence of HLA-DR1 
positivity in the recipient was not associated with an increased risk for MACCE or all-cause mortality. 
Furthermore, the interaction term between HLA-DR1 recipient and donor positivity was not significant (P = 
0.432).  
The risk for MACCE or cardiovascular mortality (Figure 5b) was also significantly increased in KTR with 
versus without HLA-DR1 positive donor after adjusting for other risk factors and when BPAR or graft loss 
were included as time-varying covariates (Table 4: Model 5 to 8). The interaction term between HLA-DR1 
recipient and donor positivity was not significant (P = 0.345). 
Discussion 
We found an association between sensitization against HLA class II, but not HLA class I, antigens prior to 
kidney transplantation and unfavourable long-term cardiac and cerebrovascular outcome. The robustness of 
this association was ascertained after adjustment for confounders and through sensitivity analyses. Our study 
is the first to investigate a negative cardiovascular outcome in KTR with pretransplant HLA class II antibodies 
and this independent of graft outcome nor incidental rejection. Also, we are the first to demonstrate that donor 
HLA-DR1 might confer an increased cardiovascular risk in KTR.  
Our results are in support of two recent studies. Sapir and co-workers demonstrated a dose-dependent 
relationship between PRA and both all-cause and cardiovascular mortality in wait-listed kidney transplant 
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candidates.
4
 In the second study, performed by Loupy and co-workers, the presence of circulating DSA six 
months after renal transplantation in patients with severe and minimal arteriosclerosis was associated with 
respectively a 2.5- and 4.1-fold increase of major cardiovascular events.
5
 Our results are of additional value 
because of the exploration of the role of preexisting HLA antibodies next to the extensive follow-up.  
A systemic inflammatory state accelerating atherogenesis or destabilising vulnerable plaques may explain our 
findings. Accumulating evidence from experimental and observational studies points to a role of 
autoimmunity and inflammation in atherosclerosis and CVD.
2 
The MHC alleles are involved in CVD of which 
HLA class II molecules are of particular interest considering their fundamental role in adaptive immunity.
11-
13,15,20,25
 They are expressed on dendritic cells (DC) within the atherosclerotic plaque and present extracellular 
peptide fragments of internalised oxidized low-density lipoprotein (OxLDL) to CD4+ T helper cells which 
secrete pro-inflammatory cyto- and chemokines.
15,26
 HLA-DR is expressed on endothelial cells of coronary 
arteries and, especially in acute coronary syndromes, its expression on these cells and on CD4
+
/CD8
+
 T cells 
is upregulated.
26,27
 HLA-DRB1 is considered to be “the notorious gene in the mosaic of auto-immunity” since 
it seems to determine the development of specific auto-antibodies and may lead to an abnormal 
immunological response to nonnoxious stimuli.
28
 According to a meta-analysis, the HLA-DRB1*01 (HLA-
DR1) allele is associated with an almost three times higher odds of antibody response after hepatitis B 
vaccination.
29
 HLA-DRB1 is particularly associated with auto-immune diseases such as SLE and rheumatoid 
arthritis; both conditions which share an increased risk of cardiovascular disease.
30-32
 In patients with SLE or 
antiphospholipid syndrome, autoantibodies were associated with accelerated atherosclerosis and 
cardiovascular events giving fuel to the hypothesis that HLA-antibodies are possibly reflecting exaggerated 
auto-immunity.
33
 
Furthermore, by decreasing the endothelial secretion of the cytoprotective and anti-inflammatory glycoprotein 
thrombomodulin, HLA class II but not class I antibodies create a prothrombotic and proinflammatory state.
17
 
The expression of HLA class II is upregulated in many autoimmune diseases and this could contribute to the 
higher incidence of CVD.
10,11,15
 Exposure to HLA class II rather than class I antibodies causes human 
allogeneic DC to preferentially differentiate naïve CD4+ T cells into follicular helper T (Tfh) cells.
34
 
Increased concentrations of circulating Tfh cells were found in patients with CAD and correlate with disease 
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activity in various autoimmune diseases.
35
 The crosstalk between DC and T cells drives the inflammatory 
response not only within the graft,
34
 but also in atherosclerotic plaques. Tfh cells expand in parallel with a loss 
of CD8+ T regulatory cells and promote atherosclerosis in murine and human aortas.
36
 
Our finding that KTR who received their graft kidney from an HLA-DR1 positive donor have a higher 
cardiovascular risk is also supported by epidemiological studies. People with type 1 diabetes with HLA class 
II haplotypes DRB1*04-DQB1*03 have a higher incidence of cardiovascular events.
15
 Also, in the general 
population and in heart transplant recipients, the haplotypes DRB1*01 and DRB1*04 were associated with a 
higher risk of CAD, myocardial infarction, a higher number of pro-inflammatory and cardiotoxic 
CD4+CD28null T cells in the peripheral blood, an increased high-sensitivity C-reactive protein, and increased 
production of interferon-ɣ upon stimulation.7,12,19,20,37 In patients with rheumatoid arthritis, the HLA 
DRB1*04 genotype was associated with increased all-cause and cardiovascular mortality and with endothelial 
dysfunction without evidence of linkage disequilibrium with TNF-genes.
10,21
 In contrast, some genome-wide 
association studies revealed no evidence of linkage of CAD to the HLA class II region,
25,38
 possibly reflecting 
the multifactorial nature of human atherosclerosis.
2
 It is likely that certain combinations of protective and 
harmful genes and nongenetic or epigenetic factors modify inflammation and promote atherogenesis.
2,12,13,20
 
In this respect, it would be interesting to further investigate the interplay between recipient and donor MHC in 
various study populations. 
Our study has strengths and limitations. Our analysis with assessment of prespecified endpoints and almost 
without missing clinical data demonstrated a robust association across different subgroup analyses after broad 
adjustment for potential confounders. Considering the absence of an association between HLA class II 
antibodies and rejection or graft loss, our results refute that the difference in cardiovascular outcome is 
attributable to differences in kidney function or premature graft loss. Our observations are reminiscent of 
registry data in KTR where HLA class II antibodies in the absence of HLA class I antibodies were not 
associated with renal graft loss.
39
 Furthermore, our finding of a negative outcome of KTR with HLA-DR1 
positive donors has a low potential for selection bias considering HLA-DR1 serostatus in the recipient is the 
sole modifier of allocation of these grafts. Of note, HLA-DR1 recipient status was not associated with 
unfavourable cardiovascular outcome in our analysis.  
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A limitation of our retrospective analysis is that we did not screen DSA on fixed time points after 
transplantation. Pretransplant anti-HLA antibodies are associated with the presence of posttransplant 
antibodies including DSA.
40
 We did not integrate DSA because of the small number of positive patients after 
transplantation in our analysis with inherent bias. Nevertheless, provided that HLA antibodies play a causal 
role in atherogenesis or in rupture of vulnerable plaques, we expect this to be especially true for DSA. In an 
attempt to overcome this limitation, we performed additional analyses excluding patients with DSA at time of 
transplantation, hereby finding an even more pronounced risk for MACCE and all-cause or cardiovascular 
mortality. Interestingly, by correlating the cPRA and the primary outcome of interest, we also found a clear 
correlation suggesting a dose dependent relationship between allosensitization and negative outcome. We 
could not correct for proteinuria and eGFR in our analyses, but we did demonstrate that there were no 
differences in eGFR assessed until 5 years posttransplantation. Considering the retrospective character of our 
study, we lack data on proteinuria in most of our study population and this could not be integrated as a time-
dependent covariate in our multivariate model. As collinearity between proteinuria and rejection can be 
suspected and as early posttransplant proteinuria is mainly associated with donor characteristics we believe 
this is not an important flaw in our analysis. Although the ongoing exposure to immunosuppressive drugs 
could also not be measured accurately, we did confirm our association of HLA class II antibodies and 
increased cardiovascular risk in first KTR as well as in patients receiving basiliximab induction.  
Most of our patients with class II antibodies had DR-antibodies (with or without DP or DQ antibodies). It was 
however not possible to differentiate between the individual antibodies. Also, in the paper by Loupy et al. this 
was a potential flaw which can and should be addressed in future prospective evaluations.
5
 Certainly, it can be 
speculated that increased granularity in the data by further separation of HLA antibodies into different 
categories will possibly decrease the likelihood of finding an association and most likely we will need registry 
data to address this important issue more thoroughly. 
Other weaknesses are the potential for unrecognized confounders, the lack of longitudinal analysis and 
qualitative assessment of HLA antibodies after transplantation and the lower sensitivity of the detection 
method in the earlier years of registration. If anything, we believe the latter has rather attenuated than 
strengthened the association demonstrated by our subanalyses according to year of transplantation.  
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We believe our findings could translate into a better risk stratification in KTR. They might also shed a new 
light on the pathophysiology of atherosclerosis, in which emerging data indicate that anti-inflammatory 
strategies might improve survival.
41
 Another interesting concept would be to examine the relationship 
between HLA class II antibodies and cardiovascular events/mortality in nontransplanted waitlisted dialysis 
patients. This hypothesis should however be tested in a large (and preferably multicenter) cohort as concerns 
of lack of power seem imminent. 
Though speculative, our findings could support an active role for micro-chimerism, which is a common but 
neglected phenomenon in KTR,
42,43
 in the pathophysiology of posttransplant CVD. Micro-chimerism has been 
associated with both graft acceptance and increased acute rejection after kidney transplantation.
36,44 
Disparities 
in its clinical effect may result from inter-patient differences in the amount or subtypes of microchimeric 
cells.
43
  
Our findings of a potential negative role of donor but not recipient HLA-DR1 serostatus might embody a 
negative immunological constellation. In lung transplant recipients, specific HLA-DR donor serotypes are 
associated with an increased risk of bronchiolitis obliterans syndrome, with established role of chronic 
immunological injury.
22
 Interestingly, in bone marrow transplant patients, smooth muscle cells of donor origin 
were found in coronary atherosclerotic plaques and not in the healthy vessel wall,
45
 providing a link between 
chimerism, inflammation and CAD. Moreover, recent data indicated an increased mortality among male 
patients who received transfusions from ever-pregnant donors.
46
 Also, multiparity especially with different 
fathers, is associated with increased cardiovascular mortality, providing indirect evidence for a role of 
alloimmunity.
47
 In a large registry study in over 100,000 solid organ transplant recipients, patient survival was 
inferior in those with a female donor.
48
 Endothelial damage by HLA antibodies may lead to a pro-
inflammatory phenotype and de novo expression of endothelial neo-antigens causing immune activation. 
Unfortunately, we lack data on pregnancy history in our female kidney donors. In a recent review, Kinder et 
al. describe the immunological implications of pregnancy-induced micro-chimerism. Apart from vertical 
transmission of maternal cells into the fetus, fetal cells can be detected in maternal blood. These micro-
chimeric cells may be target of or trigger a fetal or maternal alloimmune response. The transfer and 
persistence of microchimeric cells is influenced by genetic and external factors. However, it is unknown 
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whether micro-chimeric cells randomly seed recipient tissues or are actively recruited by chemo-attractants 
(“tissue-specific homing”) to specific fetal or maternal organs.49 
One can speculate that transplantation leads to an increased “chimeric state” by which certain (endothelial, 
dendritic, smooth muscle, …) donor cells migrate to certain recipient tissues (i.e. coronary endothelium) 
leading to a chronic inflammatory state promoting atherosclerosis and hence affecting long-term 
cardiovascular outcome.  
Conclusion 
Prior sensitization against HLA class II antigens is associated with unfavourable long-term cardiovascular 
outcome in KTR independent of effects on graft function or rejection. Transplant recipients with a HLA-DR1 
positive kidney donor also face an impaired cardiovascular outcome. Our analysis emphasizes that previous 
and future immunization after transplantation could exert intrinsic cardiotoxic effects which herald further 
investigation.  
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Figure 1: 
Kaplan-Meier survival curves for (a) MACCE or all-cause mortality and (b) MACCE or cardiovascular 
mortality in kidney transplant recipients with or without HLA class II antibodies at time of transplantation. 
HLA: human leukocyte antigen; MACCE:  major adverse cardiac and cerebrovascular event, indicating acute 
coronary syndrome, coronary revascularization, transient ischemic attack or cerebrovascular accident 
Figure 2:  
Kaplan-Meier survival curves when excluding patients with BPAR and graft loss for (a) MACCE or all-cause 
mortality and (b) MACCE or cardiovascular mortality in kidney transplant recipients with or without HLA 
class II antibodies at time of transplantation. 
BPAR: Biopsy-proven acute rejection; HLA: human leukocyte antigen; MACCE: major adverse cardiac and 
cerebrovascular event, indicating acute coronary syndrome, coronary revascularization, transient ischemic 
attack or cerebrovascular accident 
Figure 3:  
Correlation between cPRA and time to MACCE or all-cause mortality in patients with HLA class II 
antibodies. Patients without PRA were excluded in this analysis. 
cPRA: calculated panel reactive antibodies; MACCE:  major adverse cardiac and cerebrovascular event, 
indicating acute coronary syndrome, coronary revascularization, transient ischemic attack or cerebrovascular 
accident 
Figure 4:  
Forest plot demonstrating the adjusted hazard ratio for MACCE or all-cause mortality in kidney transplant 
recipients (KTR) with versus without preformed HLA class II antibodies according to subgroups. This model 
was adjusted for recipient age, recipient sex, PRA, smoking status, retransplantation, polyclonal induction, 
baseline diabetes mellitus and cardiovascular disease unless the covariate was used as a subgroup.  
BPAR: biopsy-proven acute rejection; HLA: human leukocyte antigen; MACCE:  major adverse cardiac and 
cerebrovascular event, indicating acute coronary syndrome, coronary revascularization, transient ischemic 
attack or cerebrovascular accident 
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Figure 5:  
Kaplan-Meier survival curves for (a) MACCE or all-cause mortality and (b) MACCE or cardiovascular 
mortality in kidney transplant recipients with or without an HLA-DR1 donor.  
HLA: human leukocyte antigen; MACCE:  major adverse cardiac and cerebrovascular event, indicating acute 
coronary syndrome, coronary revascularization, transient ischemic attack or cerebrovascular accident 
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TABLES 
Table 1. Baseline characteristics of the study cohort 
Characteristic 
Overall 
(N = 828) 
No HLA class II antibodies 
(N = 712) 
HLA class II antibodies 
(N = 116) 
P value 
Age recipient (years; median (IQR)) 54 (44-62) 54 (44-62) 55 (47-62) 0.272 
Sex recipient (men, %) 513 (62.0%) 464 (65.2%) 49 (42.2%) <0.001 
Non-Caucasian race (%) 43 (5.2%) 36 (5.1%) 7 (6%) 0.660 
Age donor (years, median (IQR)) 47 (36-55) 47 (35-55) 49 (37-56) 0.449 
Sex donor (men, %) 467 (56.4%) 394 (55.3%) 73 (62.9%) 0.126 
BMI category (%) 
<18.5 kg/m² 
18.5 ≤ BMI < 25 kg/m² 
25 ≤ BMI < 30 kg/m² 
≥ 30 kg/m² 
 
37 (4.7%) 
354 (42.9%) 
277 (33.6%) 
157 (19.0%) 
 
32 (4.5%) 
304 (42.8%) 
240 (33.8%) 
134 (18.9%) 
 
5 (4.3%) 
50 (43.5%) 
37 (32.2%) 
23 (20.0%) 
 
 
0.349 
 
Cause of ESRD (%) 
Hypertension 
GN 
Reflux 
PKD 
IgA nephropathy 
Diabetes 
Other/unknown 
 
17 (2.1%) 
56 (6.8%) 
36 (4.3%) 
142 (17.1%) 
81 (9.8%) 
120 (14.5%) 
376 (45.2%) 
 
14 (2.0%) 
45 (6.3%) 
33 (4.6%) 
120 (16.9%) 
77 (10.8%) 
109 (15.3%) 
314 (44.1%) 
 
3 (2.6%) 
11 (9.5%) 
3 (2.6%) 
22 (19.0%) 
4 (3.4%) 
11 (9.5%) 
62 (53.4%) 
 
 
 
 
0.080 
Dialysis vintage (days, median (IQR)) 917 (530-1425) 907 (516-1391) 1050 (596-1511) 0.208 
Waiting time (days, median (IQR)) 506 (202-1001) 480 (187-968) 641 (338-1107) 0.057 
Dialysis modality (%) 
HD 
PD 
Preemptive 
 
567 (68.5%) 
173 (20.9%) 
88 (10.6%) 
 
489 (68.7%) 
142 (19.9%) 
81 (11.4%) 
 
78 (67.2%) 
31 (26.7%) 
7 (6.0%) 
 
 
0.086 
Retransplantation (%) 
First 
Second 
Third 
 
768 (92.8%) 
56 (6.8%) 
4 (0.5%) 
 
679 (95.4%) 
32 (4.5%) 
1 (0.1%) 
 
89 (76.7%) 
24 (20.7%) 
3 (2.6%) 
 
<0.001 
<0.001 
<0.001 
Combined transplantation (%) 
Only kidney 
Kidney-Pancreas 
Kidney-Liver 
 
783 (94.6%) 
27 (3.3%) 
15 (1.8%) 
 
672 (94.4%) 
26 (3.7%) 
12 (1.7%) 
 
111 (95.7%) 
1 (0.9%) 
3 (2.6%) 
 
 
 
0.287 
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Kidney-Heart 3 (0.4%) 2 (0.3%) 1 (0.9%) 
Preexisting conditions (%) 
Diabetes mellitus 
Cardiovascular disease 
Hypertension 
 
155 (18.7%) 
155 (18.7%) 
758 (91.5%) 
 
137 (19.2%) 
134 (18.8%) 
653 (91.7%) 
 
18 (15.5%) 
21 (18.1%) 
105 (90.5%) 
 
0.340 
0.854 
0.668 
Baseline cholesterol (mg/dL, median (IQR)) 
Total cholesterol
a
 
HDL-cholesterol
b
 
LDL-cholesterol
c
 
 
180 (152-210) 
52 (41-66) 
93 (68-119) 
 
181 (152-210) 
52 (41-66) 
93 (68-119) 
 
178 (149-210) 
52 (38-66) 
90 (67-118) 
 
0.363 
0.975 
0.920 
Induction therapy (%) 
Basiliximab 
Polyclonal induction 
 
760 (91.8%) 
68 (8.2%) 
 
666 (93.5%) 
46 (6.5%) 
 
94 (81.0%) 
22 (19.0%) 
 
<0.001 
DCD donor (%) 91 (11.0%) 75 (10.5%) 16 (13.8%) 0.298 
PRA > 0% (%) 90 (10.9%) 53 (7.4%) 37 (31.9%) <0.001 
HLA-A mismatches (%) 
0 
1 
2 
HLA-B mismatches (%) 
0 
1 
2 
HLA-DR mismatches (%) 
0 
1 
2 
 
250 (30.2%) 
458 (55.3%) 
120 (14.5%) 
 
167 (20.2%) 
509 (61.5%) 
152 (18.4%) 
 
243 (29.3%) 
515 (62.2%) 
70 (8.5%) 
 
219 (30.8%) 
388 (54.5%) 
105 (14.7%) 
 
148 (20.8%) 
432 (60.7%) 
132 (18.5%) 
 
205 (28.8%) 
441 (61.9%) 
66 (9.3%) 
 
31 (26.7%) 
70 (60.3%) 
15 (12.9%) 
 
19 (16.4%) 
77 (66.4%) 
20 (17.2%) 
 
38 (32.8%) 
74 (63.8%) 
4 (3.4%) 
 
 
0.501 
 
 
 
0.454 
 
 
 
0.101 
Immunosuppressive regimen (%) 
Cyclosporine 
Tacrolimus 
mTOR inhibitors 
Other / combination 
 
103 (12.4%) 
700 (84.5%) 
15 (1.8%) 
10 (1.2%) 
 
90 (12.6%) 
600 (84.3%) 
14 (2.0%) 
8 (1.2%) 
 
13 (11.2%) 
100 (86.2%) 
1 (0.9%) 
2 (1.7%) 
 
 
 
0.495 
Smoking status (%) 
Never smoker 
Former smoker 
Current smoker 
 
388 (46.9%) 
388 (46.9%) 
52 (6.3%) 
 
325 (45.6%) 
342 (48.0%) 
45 (6.3%) 
 
63 (54.3%) 
46 (39.7%) 
7 (6.0%) 
 
 
0.212 
Posttransplant malignancy (%) 58 (7.2%) 52 (7.5%) 6 (5.4%) 0.434 
Cold ischemia time (minutes, median (IQR)) 748 (490-948) 738 (471-948) 787 (584-959) 0.179 
eGFR (mL/min, median (IQR))     
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3 months
d
 
Year 1
e
 
Year 3
f
 
Year 5
g
 
52 (42-66) 
56 (45-71) 
57 (45-70) 
58 (45-72) 
52 (42-65) 
56 (45-71) 
57 (45-70) 
56 (45-70) 
53 (40-67) 
59 (43-75) 
64 (44-77) 
63 (46-80) 
0.663 
0.678 
0.253 
0.289 
PAD (%)  39 (4.7%) 34 (4.9%) 5 (4.5%) 0.602 
Graft loss (%) 60 (7.2%) 53 (7.4%) 7 (6.0%) 0.609 
BPAR (%) 
T-cell mediated rejection  
Antibody-mediated rejection  
Missing value  
121 
95 (78.5%) 
22 (18.2%) 
4 (3.3%) 
102 
81 (79.4%) 
18 (17.6%) 
3 (2.9%) 
19 
14 (73.7%) 
4 (21.1%) 
1 (5.3%) 
 
 
0.570 
All-cause mortality (%) 84 (10.1%) 68 (9.6%) 16 (13.8%) 0.160 
MACCE or all-cause mortality (%) 138 (16.7%) 110 (15.5) 28 (24.1%) 0.021 
MACCE or cardiovascular mortality (%) 79 (9.5%) 62 (9.0%) 17 (15.3%) 0.037 
BMI: body mass index; BPAR: biopsy-proven acute rejection; DCD: donation after circulatory death; ESRD: end-stage renal disease; GN: glomerulonephritis; HD: hemodialysis; HDL: high-
density lipoprotein; HLA: human leukocyte antigen; IQR: interquartile range; LDL: low-density lipoprotein; MACCE: major adverse cardiac and cerebrovascular events; PD: peritoneal dialysis; 
PKD: polycystic kidney disease; PRA: panel reactive antibodies; SD: standard deviation 
Depicted are absolute numbers (percentages), mean ± standard deviation or median (interquartile range) depending upon the distribution. 
Overall <1% of data were missing except for 
a
:15,9%; 
b
: 18.7%; 
c
: 24.8%; 
d
: 7.9%; 
e
: 12.4%; 
f
: 13.0%; 
g
: 9.8%  
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Table 2. The hazard ratio for MACCE and all-cause or cardiovascular mortality in patients with versus without HLA class I  
or II antibodies by different modelling approaches.  
Cox Model MACCE or all-cause mortality MACCE or cardiovascular mortality 
HLA class I antibodies HR [95% CI] P value HR [95% CI] P value 
1 1.27 [0.72-2.25] 0.413 1.17 [0.54-2.54] 0.694 
2 1.16 [0.56-2.40] 0.691 1.51 [0.68-3.33] 0.312 
3 1.15 [0.56-2.39] 0.699 1.51 [0.68-3.33] 0.312 
4 1.07 [0.51-2.23] 0.863 1.45 [0.65-3.23] 0.363 
HLA class II antibodies HR [95% CI] P value HR [95% CI] P value 
1 1.65 [1.09-2.49] 0.019 1.78 [1.04-3.04] 0.036 
2 1.71 [1.13-2.60] 0.012 1.92 [1.12-3.30] 0.018 
3 1.71 [1.13-2.60] 0.012 1.92 [1.12-3.30] 0.018 
4 1.68 [1.08-2.62] 0.022 1.78 [1.02-3.10] 0.044 
Data are presented as hazard ratio (HR) with 95% confidence interval 
Model 1 included only the presence of HLA class I or II antibodies (unadjusted) 
Model 2 included the multivariate-adjustment with recipient age, recipient sex, PRA, smoking status, retransplantation, polyclonal induction, baseline diabetes mellitus and  
cardiovascular disease 
Model 3 included the same covariates as model 2 adding BPAR as time-dependent covariate 
Model 4 included the same covariates as model 2 adding graft loss as time-dependent covariate 
95%CI: 95% confidence interval; BPAR: biopsy-proven acute rejection; HLA: human leukocyte antigen; MACCE: major adverse cardiac and cerebrovascular events 
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Table 3. Secondary analyses for patients with versus without HLA class II antibodies stratiﬁed by certain subgroups. 
 HR [95% CI] P value for HR P value for interaction 
MACCE with all-cause mortality    
   BPAR 
   No BPAR 
0.47 [0.10-2.23] 
1.88 [1.22-2.92] 
0.342 
0.005 
0.227 
 
   Graft loss 
   No graft loss 
0.14 [0.01-2.13] 
1.98 [1.25-3.12] 
0.159 
0.004 
0.404 
 
   Recipient age ≤ 60 years 
   Recipient age > 60 years 
1.91 [1.05-3.49] 
1.69 [1.02-2.83] 
0.034 
0.042 
0.437 
 
   First transplantation 
   Second or more transplantation 
1.94 [1.22-3.09] 
1.60 [0.43-5.95] 
0.005 
0.487 
0.482 
 
MACCE with cardiovascular mortality    
   BPAR 
   No BPAR 
0.88 [0.15-5.14] 
1.97 [1.10-3.53] 
0.888 
0.023 
0.632 
 
   Graft loss 
   No graft loss 
1.01 [0.03-29.71] 
1.91 [1.08-3.40] 
0.997 
0.027 
0.693 
 
   Recipient age ≤ 60 years 
   Recipient age > 60 years 
1.94 [0.92-4.10] 
1.81 [0.82-4.02] 
0.081 
0.143 
0.603 
   First transplantation 
   Second or more transplantation 
1.99 [1.10-3.59] 
2.46 [0.35-17.22] 
0.023 
0.365 
0.794 
Data are presented as hazard ratio (HR) with 95% confidence interval 
95%CI: 95% confidence interval; BPAR: biopsy-proven acute rejection; HLA: human leukocyte antigen; MACCE: major adverse cardiac and cerebrovascular events  
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Table 4. The hazard ratio for MACCE and all-cause or cardiovascular mortality in patients with versus without an  
HLA- DRB1*01 donor by different subgroup-analyses.  
Cox Model 
MACCE or all-cause mortality MACCE or cardiovascular mortality 
HR [95% CI] P value HR [95% CI] P value 
5 1.45 [1.09-1.94] 0.012 1.49 [1.00-2.22] 0.050 
6 1.72 [1.31-2.26] 0.008 1.59 [1.07-2.38] 0.022 
7 1.48 [1.11-1.98] 0.008 1.59 [1.07-2.38] 0.022 
8 1.49 [1.09-2.04] 0.013 1.62 [1.08-2.41] 0.019 
Data are presented as hazard ratio (HR) with 95% confidence interval [95%CI] 
Model 5 included only the presence of donor HLA-DRB1*01 (unadjusted) 
Model 6 included the multivariate-adjustment with recipient age, recipient sex, diabetes mellitus, smoking status, polyclonal induction, baseline cardiovascular disease  
and the presence of recipient HLA- DRB1*01 
Model 7 included the same covariates as model 6 adding BPAR as time-dependent covariate 
Model 8 included the same covariates as model 6 adding graft loss as time-dependent covariate 
95%CI: 95% confidence interval; BPAR: biopsy-proven acute rejection; HLA: human leukocyte antigen; MACCE: major adverse cardiac and cerebrovascular even 
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